iBio, Inc. Form 10-Q Summary
Reporting period: Three months ended September 30, 2022, iBio’s first quarter of fiscal 2023. Financial statements are unaudited and presented under U.S. GAAP. iBio describes itself as an AI-driven precision antibody immunotherapy company. The company is transitioning away from its contract development and manufacturing organization, or CDMO, business and focusing on antibody discovery and development.
Business Context and Strategic Changes
- In September 2022, iBio acquired substantially all RubrYc Therapeutics assets, including an AI drug-discovery platform and rights to multiple immuno-oncology candidates, for approximately $1.3 million in allocated purchase price, plus potential milestone payments of up to $5.0 million.
- In November 2022, iBio announced plans to divest iBio CDMO, cease CDMO operations and reduce its workforce by approximately 60%, or 69 positions.
- The company expects the restructuring to reduce monthly cash burn by approximately half, to an estimated $2.5 million to $3.0 million, but expects approximately $1.7 million of pretax workforce-reduction charges, primarily in fiscal 2023.
- iBio’s principal continuing programs include IBIO-101, EGFRvIII, CCR8, a PD-1 agonist, IBIO-100 and the acquired RubrYc AI platform.
Key Financial Metrics
| Metric | Three months ended September 30, 2022 | Three months ended September 30, 2021 |
|---|---|---|
| Continuing-operations revenue | $0 | $84,000 |
| Research and development expense | $2.548 million | $1.134 million |
| General and administrative expense | $5.088 million | $4.175 million |
| Total operating expenses | $7.636 million | $5.309 million |
| Operating loss | $(7.636) million | $(5.225) million |
| Loss from continuing operations attributable to iBio stockholders | $(7.537) million | $(5.188) million |
| Loss from discontinued operations | $(10.593) million | $(3.751) million |
| Total net loss attributable to iBio stockholders | $(18.130) million | $(9.005) million |
| Total loss per share | $(2.05) | $(1.03) |
| Net cash used in operating activities | $(13.959) million | $(9.347) million |
Balance Sheet, Debt and Liquidity
- At September 30, 2022, cash and cash equivalents were $9.887 million, investments in debt securities were $7.599 million and restricted cash was $5.996 million.
- Total cash, cash equivalents and restricted cash were $15.883 million, compared with $28.672 million at June 30, 2022. Cash, cash equivalents and debt securities totaled approximately $17.5 million excluding restricted cash; management separately described liquidity resources including restricted cash as approximately $23.5 million.
- Total assets were $84.564 million and total liabilities were $36.196 million. Stockholders’ equity was $48.368 million, while accumulated deficit was $242.060 million.
- The term loan had a carrying value of $22.201 million and was classified as current. The loan was secured by CDMO assets and guaranteed by iBio.
- On October 11, 2022, iBio paid $5.5 million toward the term loan, agreed to apply a further $5.1 million settlement receipt to debt repayment, and agreed to make $250,000 monthly principal payments through March 2023. The lender reduced the liquidity covenant from $10.0 million to $7.5 million, with a potential reduction to $5.0 million upon a specified milestone.
- During the quarter, iBio raised approximately $1.1 million net through its at-the-market offering by selling approximately 176,000 common shares.
Material Changes Versus the Prior Comparable Period
- Continuing-operations revenue declined to zero from $84,000. iBio expects little or no near-term revenue from its pipeline and may generate future revenue from its AI platform through partnerships.
- R&D expense increased approximately 125% to $2.548 million, primarily due to personnel, the San Diego facility, pipeline investments and AI-platform activities.
- G&A expense increased approximately 22% to $5.088 million, driven primarily by higher headcount and consulting costs.
- Total net loss approximately doubled to $18.130 million, largely because of the $10.593 million loss from discontinued operations and a $4.1 million inventory and consumables write-off associated with winding down the CDMO business.
- Operating cash use increased approximately 49% to $13.959 million.
- The company’s one-for-25 reverse stock split became effective October 7, 2022, and all presented share and per-share amounts were adjusted retroactively.
Outlook, Commentary and Risks
- Management stated that available cash, cash equivalents and investments in debt securities were not expected to support operations beyond the third quarter of fiscal 2023 unless the company further reduces spending or raises capital.
- Management stated that additional capital will be required to execute the longer-term business plan and that the company is evaluating additional cost reductions, asset sales or out-licensing, capital-market financing, grants and collaborations.
- The filing states that substantial doubt exists regarding iBio’s ability to continue as a going concern beyond the third quarter of fiscal 2023. The company may violate the amended liquidity covenant on December 31, 2022 if it does not successfully extend its cash runway.
- The CDMO sale is targeted for calendar 2023, but there is no assurance regarding timing, transaction completion or proceeds. CDMO assets classified as held for sale totaled $38.778 million at September 30, 2022.
- Risks include continued operating losses, lack of product revenue, dependence on additional financing, potential equity dilution, unsuccessful asset sales or licensing transactions, clinical and development uncertainty, intellectual-property risks, supply-chain disruption, COVID-19, inflation and geopolitical instability.
- Management reported that disclosure controls and procedures were effective as of September 30, 2022, with no material changes in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Cash runway, current unrestricted liquidity and compliance with the amended Woodforest liquidity covenant.
- Status, timing and expected proceeds of the proposed CDMO and facility divestiture.
- Actual cash severance and restructuring costs compared with the approximately $1.7 million estimate.
- Progress and funding requirements for IBIO-101, EGFRvIII, CCR8, the PD-1 agonist and other pipeline programs.
- Terms and potential dilution from future equity offerings, stock awards, warrants and milestone payments related to the RubrYc transaction.
- Collection and application of the remaining $5.1 million Fraunhofer settlement receivable and the $900,000 license-related receivable.
- Whether the company can reduce monthly burn to the stated $2.5 million to $3.0 million range while maintaining development activities.
- The filing text contains inconsistent references to fiscal-year periods in its risk-factor discussion; investors should reconcile those references with the company’s subsequent filings and audited financial statements.